A Phase I A/B Study of the Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 14 Feb 2019
Price : $35 *
At a glance
- Drugs EC 1456 (Primary) ; Technetium Tc99m etarfolatide (Primary)
- Indications Advanced breast cancer; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Endocyte
- 06 Feb 2019 Status changed from active, no longer recruiting to completed.
- 23 Jul 2018 Planned End Date changed from 30 Jan 2018 to 31 Jul 2018.
- 02 Apr 2018 Planned End Date changed from 1 Jan 2018 to 30 Jan 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History